Inspire Medical Systems (NYSE: INSP) appointed Carlton Weatherby as its chief strategy officer (CSO).
Weatherby’s appointment goes into effect today, July 24, 2023. He joins Inspire from Medtronic, most recently serving as VP and GM of the medtech giant’s Spine & Biologics business. Weatherby took on that role in 2021, previously serving as VP of strategic sales. He had various roles in corporate development in his time at Medtronic, which he originally joined in 2011.
Inspire said in a news release that Weatherby brings more than 15 years of experience in commercial and corporate strategy and business development in medical devices.
“We are very excited to welcome Carlton to the Inspire team,” said Tim Herbert, president and CEO. “Carlton’s vast experience in leadership roles across medtech, as well as his strategic vision, will be very valuable to us as we continue to grow and scale as an organization.”
Inspire Medical Systems develops minimally invasive solutions for patients with obstructive sleep apnea (OSA). The proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that treats moderate to severe OSA. It offers an alternative to traditional positive airway pressure (PAP) therapy in the sleep respiratory market.
“I am thrilled to be joining Inspire at such an exciting inflection point in the company’s maturation,” said Weatherby. “I look forward to shaping the company’s strategy in the years to come and contributing to Inspire’s mission of serving the many patients with untreated OSA.”
Inspire’s sleep apnea treatment market share continues to grow since a severe recall knocked traditional PAP maker Philips out of the market for a while. Just last quarter, Inspire posted better than 83% revenue growth and increased its full-year guidance, projecting 42% to 45% year-over-year growth.
